Online citations, reference lists, and bibliographies.
← Back to Search

Biomarkers For Malignant Pleural Mesothelioma: Current Status.

L. Greillier, P. Baas, J. Welch, B. Hasan, A. Passioukov
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose main etiology is exposure to asbestos fibers. The incidence of MPM is anticipated to increase worldwide during the first half of this century. For various reasons, MPM is difficult to diagnose and is notoriously refractory to most treatments. However, recently two active chemotherapy regimens have been demonstrated to significantly increase survival in patients with MPM, and several therapeutic agents and strategies are currently under evaluation.Researchers have actively sought MPM biomarkers for more than 20 years. Biomarkers would be helpful in managing three clinical aspects of MPM: early diagnosis, prognosis, and treatment outcome prediction. The aims of the present review are to summarize the published and recently presented data on MPM biomarkers and to identify the prospects for future translational research projects.Among the 'classical' diagnostic biomarkers measured in biological fluids, such as cytokeratins and cell surface antigens, none discriminate patients with MPM from those with other malignancies and nonmalignant diseases. Osteopontin, soluble mesothelin, and megakaryocyte potentiating factor (MPF) appear to be the most promising of the recent biomarkers, but are still subject to some limitations. Osteopontin lacks specificity for mesothelioma, while both soluble mesothelin and MPF lack sensitivity for detecting non-epithelial subtypes. Panels consisting of a small set of biomarkers do not improve the diagnostic yield, and results from molecular profiling are too preliminary to be brought into daily clinical practice. While a large number of biomarkers have been assessed in biological fluids and tumor tissue for their prognostic value, none have had a widespread impact on clinical practice. In contrast, data concerning predictive biomarkers are very limited, even though they are most interesting from the perspective of clinicians.Additional prospective studies, in large and independent samples of patients, with rigorous statistical methodology and standardized laboratory techniques are now warranted to validate and define the precise value of diagnostic and prognostic MPM biomarkers. Future research efforts should focus on biomarkers predictive of the efficacy and toxicity of standard chemotherapy. Translational research should be systematically incorporated into the design of clinical trials assessing new targeted agents in MPM.



This paper is referenced by
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
ASBESTOS (CHRYSOTILE, AMOSITE, CROCIDOLITE, TREMOLITE, ACTINOLITE, AND ANTHOPHYLLITE)
(2012)
10.1016/s0003-2670(00)84695-4
DIESEL AND GASOLINE ENGINE EXHAUSTS AND SOME NITROARENES. IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS.
humAn cArcinogens (2014)
10.21037/shc.2018.04.01
Modern diagnostic and therapeutic interventional pulmonology in mesothelioma
Rachelle Asciak (2018)
10.1159/000339259
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up†
P. Baas (2015)
10.3978/j.issn.2072-1439.2013.06.12
The challenge of prognostic markers in pleural mesothelioma.
A. Imperatori (2013)
10.1097/JTO.0b013e31820db125
MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma
Veronica Balatti (2011)
Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.
H. Lin (2014)
10.18632/oncotarget.17910
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
Sabrina Lagniau (2017)
An electronic nose in respiratory disease
Silvano Dragonieri (2012)
10.1097/CAD.0b013e328341ccdd
Targeted therapies in malignant pleural mesothelioma: a review of clinical studies
L. Greillier (2011)
10.1016/j.lungcan.2011.08.009
An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
S. Dragonieri (2012)
10.1097/MCP.0b013e32832b98eb
Serum and pleural fluid biomarkers for mesothelioma
J. Creaney (2009)
III Italian Consensus Conference on Malignant Mesothelioma of the Pleura. Epidemiology, Public Health and Occupational Medicine related issues.
C. Magnani (2015)
10.1177/172460080902400208
Osteopontin is not a Specific Marker in Malignant Pleural Mesothelioma
Laura Paleari (2009)
10.5582/bst.2016.01249
Progress of research on microRNAs with diagnostic value in asbestos exposure: A call for method standardization.
Luigina Micolucci (2017)
10.3978/j.issn.2072-1439.2013.03.03
The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
T. Mori (2013)
UvA-DARE ( Digital Academic Repository ) An electronic nose in respiratory disease
S. Dragonieri (2012)
10.1002/jcb.27586
Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa‐miR‐2053 and lncRNA‐RP1‐86D1.3 axis expression in malignant pleural mesothelioma
M. Matboli (2019)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1038/onc.2011.623
DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin
A. Mitra (2012)
10.18632/oncotarget.12408
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers
I. Bononi (2016)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1007/s10637-017-0535-z
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma
A. De (2017)
10.1038/bjc.2013.9
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
D. Pinato (2013)
10.1186/1471-2407-10-242
Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients
I. Raiko (2009)
10.3390/medicina55060267
In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma
E. Rouka (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar